Keros Therapeutics (KROS) Gains from Investment Securities (2020 - 2025)

Keros Therapeutics has reported Gains from Investment Securities for 6 years, with the latest figure at -$14000.0 in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities rose 99.76% year-over-year to -$14000.0; the trailing twelve-month figure through Dec 2025 stood at -$14000.0 (changed N/A YoY), and the FY2023 full-year result was $1.3 million, down 91.32% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at -$14000.0, up from -$5.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $15.4 million in Q4 2022, with the low at -$5.7 million in Q4 2024.
• Historically, Gains from Investment Securities has averaged $2.4 million across 5 years, with a median of -$4000.0 in 2023.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities jumped 40.91% — and 2022, when it surged 59419.23%.
• Keros Therapeutics' Gains from Investment Securities stood at -$26000.0 in 2021, then surged by 59419.23% to $15.4 million in 2022, then plunged by 91.3% to $1.3 million in 2023, then plunged by 527.5% to -$5.7 million in 2024, then surged by 99.76% to -$14000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$14000.0 (Q4 2025), -$5.7 million (Q4 2024), and $5.7 million (Q3 2024), per Business Quant data.